COVID-19 in a patient with advanced Merkel cell carcinoma receiving immunotherapy.
Identifieur interne : 000C63 ( Main/Corpus ); précédent : 000C62; suivant : 000C64COVID-19 in a patient with advanced Merkel cell carcinoma receiving immunotherapy.
Auteurs : Cesar Martins Da Costa ; Zenaide Silva De Souza ; Alessandra Corte Real Salgues ; Guilherme Harada ; Pedro Paulo Marino Rodrigues Ayres ; Daniela Bulh Es Vieira Nunes ; Artur Katz ; Rodrigo Ramella MunhozSource :
- Immunotherapy [ 1750-7448 ] ; 2020.
English descriptors
- KwdEn :
- Aged (MeSH), Antibodies, Monoclonal, Humanized (therapeutic use), Antineoplastic Agents, Immunological (therapeutic use), Betacoronavirus (MeSH), COVID-19 (MeSH), Carcinoma, Merkel Cell (complications), Carcinoma, Merkel Cell (pathology), Carcinoma, Merkel Cell (therapy), Coronavirus Infections (complications), Coronavirus Infections (diagnosis), Coronavirus Infections (pathology), Coronavirus Infections (therapy), Humans (MeSH), Immunotherapy (adverse effects), Lung (diagnostic imaging), Lung (pathology), Male (MeSH), Pandemics (MeSH), Pneumonia, Viral (complications), Pneumonia, Viral (diagnosis), Pneumonia, Viral (pathology), Pneumonia, Viral (therapy), Programmed Cell Death 1 Receptor (antagonists & inhibitors), SARS-CoV-2 (MeSH), Skin Neoplasms (complications), Skin Neoplasms (pathology), Skin Neoplasms (therapy), Tomography, X-Ray Computed (MeSH), Treatment Outcome (MeSH).
- MESH :
- chemical , antagonists & inhibitors : Programmed Cell Death 1 Receptor.
- chemical , therapeutic use : Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological.
- adverse effects : Immunotherapy.
- complications : Carcinoma, Merkel Cell, Coronavirus Infections, Pneumonia, Viral, Skin Neoplasms.
- diagnosis : Coronavirus Infections, Pneumonia, Viral.
- diagnostic imaging : Lung.
- pathology : Carcinoma, Merkel Cell, Coronavirus Infections, Lung, Pneumonia, Viral, Skin Neoplasms.
- therapy : Carcinoma, Merkel Cell, Coronavirus Infections, Pneumonia, Viral, Skin Neoplasms.
- Aged, Betacoronavirus, COVID-19, Humans, Male, Pandemics, SARS-CoV-2, Tomography, X-Ray Computed, Treatment Outcome.
Abstract
Background: Little is known about the 2019 novel coronavirus disease (COVID-19) course and outcomes in patients receiving immunotherapy. Here we describe a metastatic Merkel cell carcinoma patient with a severe acute respiratory syndrome coronavirus 2 infection while receiving pembrolizumab. Case presentation: A 66-year-old man, with a metastatic Merkel cell carcinoma receiving pembrolizumab, presented with fever. Chest computed tomography (CT) showed pulmonary ground-glass opacities, suggesting viral or immuno-related etiology. On day 7, the patient was hospitalized due to dyspnea and worsening of the radiological findings. Real time polymerase chain reaction (RT-PCR) testing confirmed COVID-19. The patient developed acute respiratory distress syndrome and acute kidney injury. Hydroxychloroquine was administered for 5 days, but discontinued after supraventricular extrasystoles. Clinical improvement allowed the patient's discharge after 81 days of hospitalization. Conclusion: A careful evaluation of oncologic patients receiving immunotherapy during the COVID-19 pandemic is of utmost importance.
DOI: 10.2217/imt-2020-0193
PubMed: 32900245
PubMed Central: PMC7480322
Links to Exploration step
pubmed:32900245Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">COVID-19 in a patient with advanced Merkel cell carcinoma receiving immunotherapy.</title><author><name sortKey="Da Costa, Cesar Martins" sort="Da Costa, Cesar Martins" uniqKey="Da Costa C" first="Cesar Martins" last="Da Costa">Cesar Martins Da Costa</name><affiliation><nlm:affiliation>Oncology Center, Hospital Sírio-Libanês (HSL), São Paulo, SP, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="De Souza, Zenaide Silva" sort="De Souza, Zenaide Silva" uniqKey="De Souza Z" first="Zenaide Silva" last="De Souza">Zenaide Silva De Souza</name><affiliation><nlm:affiliation>Oncology Center, Hospital Sírio-Libanês (HSL), São Paulo, SP, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Real Salgues, Alessandra Corte" sort="Real Salgues, Alessandra Corte" uniqKey="Real Salgues A" first="Alessandra Corte" last="Real Salgues">Alessandra Corte Real Salgues</name><affiliation><nlm:affiliation>Oncology Center, Hospital Sírio-Libanês (HSL), São Paulo, SP, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Harada, Guilherme" sort="Harada, Guilherme" uniqKey="Harada G" first="Guilherme" last="Harada">Guilherme Harada</name><affiliation><nlm:affiliation>Oncology Center, Hospital Sírio-Libanês (HSL), São Paulo, SP, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Marino Rodrigues Ayres, Pedro Paulo" sort="Marino Rodrigues Ayres, Pedro Paulo" uniqKey="Marino Rodrigues Ayres P" first="Pedro Paulo" last="Marino Rodrigues Ayres">Pedro Paulo Marino Rodrigues Ayres</name><affiliation><nlm:affiliation>Intensive Care Medicine, Hospital Sírio-Libanês (HSL), São Paulo, SP, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Vieira Nunes, Daniela Bulh Es" sort="Vieira Nunes, Daniela Bulh Es" uniqKey="Vieira Nunes D" first="Daniela Bulh Es" last="Vieira Nunes">Daniela Bulh Es Vieira Nunes</name><affiliation><nlm:affiliation>Intensive Care Medicine, Hospital Sírio-Libanês (HSL), São Paulo, SP, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Katz, Artur" sort="Katz, Artur" uniqKey="Katz A" first="Artur" last="Katz">Artur Katz</name><affiliation><nlm:affiliation>Oncology Center, Hospital Sírio-Libanês (HSL), São Paulo, SP, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Munhoz, Rodrigo Ramella" sort="Munhoz, Rodrigo Ramella" uniqKey="Munhoz R" first="Rodrigo Ramella" last="Munhoz">Rodrigo Ramella Munhoz</name><affiliation><nlm:affiliation>Oncology Center, Hospital Sírio-Libanês (HSL), São Paulo, SP, Brazil.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32900245</idno><idno type="pmid">32900245</idno><idno type="doi">10.2217/imt-2020-0193</idno><idno type="pmc">PMC7480322</idno><idno type="wicri:Area/Main/Corpus">000C63</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000C63</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">COVID-19 in a patient with advanced Merkel cell carcinoma receiving immunotherapy.</title><author><name sortKey="Da Costa, Cesar Martins" sort="Da Costa, Cesar Martins" uniqKey="Da Costa C" first="Cesar Martins" last="Da Costa">Cesar Martins Da Costa</name><affiliation><nlm:affiliation>Oncology Center, Hospital Sírio-Libanês (HSL), São Paulo, SP, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="De Souza, Zenaide Silva" sort="De Souza, Zenaide Silva" uniqKey="De Souza Z" first="Zenaide Silva" last="De Souza">Zenaide Silva De Souza</name><affiliation><nlm:affiliation>Oncology Center, Hospital Sírio-Libanês (HSL), São Paulo, SP, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Real Salgues, Alessandra Corte" sort="Real Salgues, Alessandra Corte" uniqKey="Real Salgues A" first="Alessandra Corte" last="Real Salgues">Alessandra Corte Real Salgues</name><affiliation><nlm:affiliation>Oncology Center, Hospital Sírio-Libanês (HSL), São Paulo, SP, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Harada, Guilherme" sort="Harada, Guilherme" uniqKey="Harada G" first="Guilherme" last="Harada">Guilherme Harada</name><affiliation><nlm:affiliation>Oncology Center, Hospital Sírio-Libanês (HSL), São Paulo, SP, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Marino Rodrigues Ayres, Pedro Paulo" sort="Marino Rodrigues Ayres, Pedro Paulo" uniqKey="Marino Rodrigues Ayres P" first="Pedro Paulo" last="Marino Rodrigues Ayres">Pedro Paulo Marino Rodrigues Ayres</name><affiliation><nlm:affiliation>Intensive Care Medicine, Hospital Sírio-Libanês (HSL), São Paulo, SP, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Vieira Nunes, Daniela Bulh Es" sort="Vieira Nunes, Daniela Bulh Es" uniqKey="Vieira Nunes D" first="Daniela Bulh Es" last="Vieira Nunes">Daniela Bulh Es Vieira Nunes</name><affiliation><nlm:affiliation>Intensive Care Medicine, Hospital Sírio-Libanês (HSL), São Paulo, SP, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Katz, Artur" sort="Katz, Artur" uniqKey="Katz A" first="Artur" last="Katz">Artur Katz</name><affiliation><nlm:affiliation>Oncology Center, Hospital Sírio-Libanês (HSL), São Paulo, SP, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Munhoz, Rodrigo Ramella" sort="Munhoz, Rodrigo Ramella" uniqKey="Munhoz R" first="Rodrigo Ramella" last="Munhoz">Rodrigo Ramella Munhoz</name><affiliation><nlm:affiliation>Oncology Center, Hospital Sírio-Libanês (HSL), São Paulo, SP, Brazil.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Immunotherapy</title><idno type="eISSN">1750-7448</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Antineoplastic Agents, Immunological (therapeutic use)</term><term>Betacoronavirus (MeSH)</term><term>COVID-19 (MeSH)</term><term>Carcinoma, Merkel Cell (complications)</term><term>Carcinoma, Merkel Cell (pathology)</term><term>Carcinoma, Merkel Cell (therapy)</term><term>Coronavirus Infections (complications)</term><term>Coronavirus Infections (diagnosis)</term><term>Coronavirus Infections (pathology)</term><term>Coronavirus Infections (therapy)</term><term>Humans (MeSH)</term><term>Immunotherapy (adverse effects)</term><term>Lung (diagnostic imaging)</term><term>Lung (pathology)</term><term>Male (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (complications)</term><term>Pneumonia, Viral (diagnosis)</term><term>Pneumonia, Viral (pathology)</term><term>Pneumonia, Viral (therapy)</term><term>Programmed Cell Death 1 Receptor (antagonists & inhibitors)</term><term>SARS-CoV-2 (MeSH)</term><term>Skin Neoplasms (complications)</term><term>Skin Neoplasms (pathology)</term><term>Skin Neoplasms (therapy)</term><term>Tomography, X-Ray Computed (MeSH)</term><term>Treatment Outcome (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Programmed Cell Death 1 Receptor</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Antineoplastic Agents, Immunological</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Immunotherapy</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Carcinoma, Merkel Cell</term><term>Coronavirus Infections</term><term>Pneumonia, Viral</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Lung</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Carcinoma, Merkel Cell</term><term>Coronavirus Infections</term><term>Lung</term><term>Pneumonia, Viral</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Carcinoma, Merkel Cell</term><term>Coronavirus Infections</term><term>Pneumonia, Viral</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Betacoronavirus</term><term>COVID-19</term><term>Humans</term><term>Male</term><term>Pandemics</term><term>SARS-CoV-2</term><term>Tomography, X-Ray Computed</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><b>Background:</b> Little is known about the 2019 novel coronavirus disease (COVID-19) course and outcomes in patients receiving immunotherapy. Here we describe a metastatic Merkel cell carcinoma patient with a severe acute respiratory syndrome coronavirus 2 infection while receiving pembrolizumab. <b>Case presentation:</b> A 66-year-old man, with a metastatic Merkel cell carcinoma receiving pembrolizumab, presented with fever. Chest computed tomography (CT) showed pulmonary ground-glass opacities, suggesting viral or immuno-related etiology. On day 7, the patient was hospitalized due to dyspnea and worsening of the radiological findings. Real time polymerase chain reaction (RT-PCR) testing confirmed COVID-19. The patient developed acute respiratory distress syndrome and acute kidney injury. Hydroxychloroquine was administered for 5 days, but discontinued after supraventricular extrasystoles. Clinical improvement allowed the patient's discharge after 81 days of hospitalization. <b>Conclusion:</b> A careful evaluation of oncologic patients receiving immunotherapy during the COVID-19 pandemic is of utmost importance.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32900245</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>13</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1750-7448</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>15</Issue><PubDate><Year>2020</Year><Month>10</Month></PubDate></JournalIssue><Title>Immunotherapy</Title><ISOAbbreviation>Immunotherapy</ISOAbbreviation></Journal><ArticleTitle>COVID-19 in a patient with advanced Merkel cell carcinoma receiving immunotherapy.</ArticleTitle><Pagination><MedlinePgn>1133-1138</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2217/imt-2020-0193</ELocationID><Abstract><AbstractText><b>Background:</b> Little is known about the 2019 novel coronavirus disease (COVID-19) course and outcomes in patients receiving immunotherapy. Here we describe a metastatic Merkel cell carcinoma patient with a severe acute respiratory syndrome coronavirus 2 infection while receiving pembrolizumab. <b>Case presentation:</b> A 66-year-old man, with a metastatic Merkel cell carcinoma receiving pembrolizumab, presented with fever. Chest computed tomography (CT) showed pulmonary ground-glass opacities, suggesting viral or immuno-related etiology. On day 7, the patient was hospitalized due to dyspnea and worsening of the radiological findings. Real time polymerase chain reaction (RT-PCR) testing confirmed COVID-19. The patient developed acute respiratory distress syndrome and acute kidney injury. Hydroxychloroquine was administered for 5 days, but discontinued after supraventricular extrasystoles. Clinical improvement allowed the patient's discharge after 81 days of hospitalization. <b>Conclusion:</b> A careful evaluation of oncologic patients receiving immunotherapy during the COVID-19 pandemic is of utmost importance.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>da Costa</LastName><ForeName>Cesar Martins</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0000-0003-1753-6840</Identifier><AffiliationInfo><Affiliation>Oncology Center, Hospital Sírio-Libanês (HSL), São Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Souza</LastName><ForeName>Zenaide Silva</ForeName><Initials>ZS</Initials><Identifier Source="ORCID">0000-0002-9743-191X</Identifier><AffiliationInfo><Affiliation>Oncology Center, Hospital Sírio-Libanês (HSL), São Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Real Salgues</LastName><ForeName>Alessandra Corte</ForeName><Initials>AC</Initials><Identifier Source="ORCID">0000-0002-9642-2237</Identifier><AffiliationInfo><Affiliation>Oncology Center, Hospital Sírio-Libanês (HSL), São Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harada</LastName><ForeName>Guilherme</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-4012-3251</Identifier><AffiliationInfo><Affiliation>Oncology Center, Hospital Sírio-Libanês (HSL), São Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marino Rodrigues Ayres</LastName><ForeName>Pedro Paulo</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>Intensive Care Medicine, Hospital Sírio-Libanês (HSL), São Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieira Nunes</LastName><ForeName>Daniela Bulhões</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>Intensive Care Medicine, Hospital Sírio-Libanês (HSL), São Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katz</LastName><ForeName>Artur</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Oncology Center, Hospital Sírio-Libanês (HSL), São Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munhoz</LastName><ForeName>Rodrigo Ramella</ForeName><Initials>RR</Initials><Identifier Source="ORCID">0000-0001-8898-2798</Identifier><AffiliationInfo><Affiliation>Oncology Center, Hospital Sírio-Libanês (HSL), São Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Immunotherapy</MedlineTA><NlmUniqueID>101485158</NlmUniqueID><ISSNLinking>1750-743X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>DPT0O3T46P</RegistryNumber><NameOfSubstance UI="C582435">pembrolizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000074322" MajorTopicYN="N">Antineoplastic Agents, Immunological</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015266" MajorTopicYN="N">Carcinoma, Merkel Cell</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="Y">Immunotherapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061026" MajorTopicYN="N">Programmed Cell Death 1 Receptor</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012878" MajorTopicYN="N">Skin Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">Merkel cell carcinoma</Keyword><Keyword MajorTopicYN="Y">SARS-CoV-2</Keyword><Keyword MajorTopicYN="Y">anti-PD-1 therapy</Keyword><Keyword MajorTopicYN="Y">coronavirus</Keyword><Keyword MajorTopicYN="Y">immune-related adverse events</Keyword><Keyword MajorTopicYN="Y">immunotherapy</Keyword><Keyword MajorTopicYN="Y">oncology</Keyword><Keyword MajorTopicYN="Y">pandemic</Keyword><Keyword MajorTopicYN="Y">skin cancer</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>9</Day><Hour>5</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32900245</ArticleId><ArticleId IdType="doi">10.2217/imt-2020-0193</ArticleId><ArticleId IdType="pmc">PMC7480322</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cancer Manag Res. 2017 Jun 14;9:207-213</Citation><ArticleIdList><ArticleId IdType="pubmed">28652812</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Nucl Med. 2020 Aug;45(8):e381-e382</Citation><ArticleIdList><ArticleId IdType="pubmed">32520508</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Apr 30;382(18):1708-1720</Citation><ArticleIdList><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer. 2020 Sep 1;126(17):3900-3906</Citation><ArticleIdList><ArticleId IdType="pubmed">32478867</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Oncol. 2020 Jul 1;6(7):1108-1110</Citation><ArticleIdList><ArticleId IdType="pubmed">32211820</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Respir Med. 2018 Jun;6(6):472-478</Citation><ArticleIdList><ArticleId IdType="pubmed">29856320</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Oncol. 2019 Jul 18;:</Citation><ArticleIdList><ArticleId IdType="pubmed">31318407</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Discov. 2020 Aug;10(8):1121-1128</Citation><ArticleIdList><ArticleId IdType="pubmed">32398243</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunotherapy. 2020 Jun;12(8):545-548</Citation><ArticleIdList><ArticleId IdType="pubmed">32349579</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Immunol. 2018 Jul;19(7):723-732</Citation><ArticleIdList><ArticleId IdType="pubmed">29915296</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Surg Oncol. 2020 Jun;46(6):1194-1195</Citation><ArticleIdList><ArticleId IdType="pubmed">32376146</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Oncol. 2020 Mar;21(3):335-337</Citation><ArticleIdList><ArticleId IdType="pubmed">32066541</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Oncol. 2020 Jul;21(7):914-922</Citation><ArticleIdList><ArticleId IdType="pubmed">32539942</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Cancer. 2018 Oct;119(8):950-960</Citation><ArticleIdList><ArticleId IdType="pubmed">30318514</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2020 Aug;26(8):1218-1223</Citation><ArticleIdList><ArticleId IdType="pubmed">32581323</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2019 Jan 15;321(2):131-133</Citation><ArticleIdList><ArticleId IdType="pubmed">30566194</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Oncol. 2020 Jul;31(7):894-901</Citation><ArticleIdList><ArticleId IdType="pubmed">32224151</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Respir Rev. 2019 Nov 6;28(154):</Citation><ArticleIdList><ArticleId IdType="pubmed">31694838</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Oncol Rep. 2020 May 8;22(5):53</Citation><ArticleIdList><ArticleId IdType="pubmed">32385672</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Oncol. 2018 Dec 1;4(12):1721-1728</Citation><ArticleIdList><ArticleId IdType="pubmed">30242316</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 2020 Jul 17;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32678948</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Mol Immunol. 2020 May;17(5):533-535</Citation><ArticleIdList><ArticleId IdType="pubmed">32203188</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C63 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000C63 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32900245
|texte= COVID-19 in a patient with advanced Merkel cell carcinoma receiving immunotherapy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32900245" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |